NTLA Q4 2022 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+5.6% YoY

Gross Profit

-$86M-637.0% margin

Operating Income

-$110M-811.1% margin

Net Income

-$113M-835.5% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

-$90M

Free Cash Flow

-$94M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$285M

Stockholders' Equity

$1.2B

Cash & Equivalents

$524M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$13M	+5.6%
Gross Profit	-$86M	-$58M	-48.3%
Operating Income	-$110M	-$80M	-36.9%
Net Income	-$113M	-$81M	-39.6%